• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Tuberculosis
 

Tuberculosis

on

  • 32 views

 

Statistics

Views

Total Views
32
Views on SlideShare
32
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Tuberculosis Tuberculosis Presentation Transcript

    • By Abhinav Sawhney M. Pharmacy (Pharmacology) Amity Institute of Pharmacy Amity University Noida. M. tuberculosis
    • TB Transmission What is TB? TB is a disease caused by infection with a bacteria called Mycobacterium tuberculosis.
    • How Are TB Germs Spread?
    • TB Transmission How can you catch TB? TB is spread through tiny drops sprayed into the air when an infected person coughs, sneezes, or speaks, or another person breathes the air into their lungs containing the TB bacteria.
    • How Are TB Germs Spread?  TB germs are passed through the air when a person who is sick with TB disease coughs, sings, sneezes, or laughs  To become infected with TB germs, a person usually needs to share air space with someone sick with TB disease (e.g., live, work, or play together)  The amount of time, the environment, and how sick the person is all contribute to whether or not you get infected  In most cases, your body is able to fight off the germs
    • TB Infection vs. TB Disease  There is a difference between TB “infection” and TB “disease”  TB infection: TB germs stay in your lungs, but they do not multiply or make you sick  You cannot pass TB germs to others  TB disease: TB germs stay in your lungs or move to other parts of your body, multiply, and make you sick  You can pass the TB germs to other people
    • Tuberculosis in Humans - Reservoir: Humans - Transmission: Airborne disease (aerosol transmission) - Symptoms: Latent TB infection: Active TB infection: No symptoms Bad cough *Cannot spread TB Coughing up blood/sputum Chest pain Loss of appetite Weight loss Fever Chills Night sweats Swollen glands *Contagious Extra-pulmonary TB: Symptoms depend on location of infection General symptoms: fatigue, fever, loss of appetite, weight loss. TB of lymph nodes: swelling of lymph nodes TB meningitis: neurological symptoms including headache Spinal TB: Mobility impairments, pain
    • Mycobacterium Tuberculosis General Characteristics - Family – Myobacteria - Gram-positive aerobic rod-shaped bacilli - “Acid fast” bacteria - Lack of spore formation and toxin production - No capsule, flagellum (non-motile) - Generation time of 18- 24 hours but requires 3-4 weeks for visual colonies Pathological Features - Principle cause of Human Tuberculosis - Intracellular pathogen (alveolar macrophages) - Waxy, thick, complex cellular envelope - Cell envelope components ex) sulfolipids - Produces tubercles, localized lesions of M. tuberculosis SEM of M. tuberculosis M. Tuberculosis (stained in purple)
    • Mycobacterial Cellular Envelope General Features - Thick, waxy and complex - Higher fluidity in more external regions than internal regions - Relatively impermeable to hydrophilic solutes - Contain porins (selective cationic channels) Main Components - Peptidoglycan  contains N-glycolylmuramic acid instead of N-acetylmuramic acid - Arabinogalactan - Mycolic Acids (60% of cellular envelope) - Lipoarabinomannan (LAM)
    • Mycobacterial Cellular Envelope
    • Contribution of Mycobacterial Cellular Envelope to Pathogenesis Resistance to Drying and Other Environmental Factors - Thick, waxy nature of cellular envelope protects M. tuberculosis from drying, alkali conditions, and chemical disinfectants - Hinders entrance of antimicrobial agents Entry into Host Cells - Lipoarabinomannan (LAM) binds to mannose receptors on alveolar macropages leading to entry into the cell Interference of Host Immune Response - Glycolipids and sulfolipids decrease the effects of oxidative cytotoxic mechanism - Inhibition of phagosome and lysosome fusion inside macrophage - Waxy cellular envelope prevents acidification of the bacteria inside the phagosome
    • Factors Affecting Pathogenicity Active Infection - Only individuals with an active infection can transmit the disease Transmission - Aerosolized droplets need to be <10μm in order to evade the ciliated epithelium of the lung to establish infection in the terminal alveoli Growth & Structure - Only require a very few number of bacteria to establish an infection (1-10 bacteria) - Slow generation time M. Tuberculosis in sputum (stained in red)
    • Common Symptoms of TB Disease  Cough (2-3 weeks or more)  Coughing up blood  Chest pains  Fever  Night sweats  Feeling weak and tired  Losing weight without trying  Decreased or no appetite  If you have TB outside the lungs, you may have other symptoms
    • Diagnosis of Latent & Active TB Tools for Diagnosing TB Infection Mantoux skin test (PPD) Chest x-ray Sputum cultures
    • Diagnosis for Latent & Active TB Tools for Diagnosing TB Infection Mantoux Skin Test(PPD) Mantoux tuberculin skin test (PPD) is a skin test for identifying exposure to the TB bacteria, Mycobacterium tuberculosis (latent infection) The Mantoux test is recommended because it provides the most consistent and reliable result. The Mantoux test is read 48-72 hours after administration. Induration or “knot-like” swelling at the test site is significant and the reaction is measured in millimeter units. Redness at the test site is not measured.
    • Diagnosis for Latent & Active TB Tools for Diagnosing TB Infection Sputum A sputum specimen is necessary to confirm that the TB bacteria is present in the lung. The sputum specimens should: -come from deep within the lungs; -be obtained from the first coughed up sputum of the day, for 3 consecutive days -may be obtained through special respiratory therapy procedures.
    • Treatment for TB Disease  TB disease is treated with medicine to kill the TB germs  Usually, the treatment will last for 6-9 months  TB disease can be cured if the medicine is taken as prescribed, even after you no longer feel sick
    • Treatment Antibacterial chemotherapy: - Combination of first and second line drugs for the first 2 months which could include: - Isoniazid - Rifampicin - Pyrazinamide - Streptomycin or Ethambutol - Next 4 months, combination of: - Isoniazid - Rifampicin - Early resistance to isoniazid: other first-line drugs such as ethambutol, streptomycin, pyrazinamide and fluoroquinolones can be added to drug arsenal (treatment period also extended). - These drugs are relatively effective in killing the bacteria, however, they also produce a wide variety of side effects.
    • Treatment First line drugs: - Bactericidal agents: kill active bacteria, important in the early stages of infection. Second line drugs: - Bacteriostatic: hinder bacterial growth. - Strengthen treatment in the case of resistant bacteria. - Less efficient and generally more toxic than first line drugs. Inappropriate chemotherapy: - Monotherapy (single drug treatment) - Decreased treatment period - Low absorption of drugs
    • Drug Bactericidal or Bacteriostatic Mechanism of Action Mutation Rate Side Effects Isoniazid Bactericidal to rapidly dividing bacteria and bacteriostatic to slowly dividing bacteria Pro-drug: activated by a bacterial catalase. Inhibits enoyl-ACP reductase (key enzyme in fatty acid synthesis, different than equivalent mammalian enzymes) 1 in 105 - 106 Rash, abnormal liver function, anemia, peripheral neuropathy, mild CNS effects Rifampicin Bactericidal Inhibits transcription by RNA polymerase 1 in 108 Fever, immune reactions, GI irritation, liver damage, can cause tears and urine to turn red/orange Streptomycin Bactericidal Inhibits initiation of protein synthesis 1 in 108 - 109 Damage to the ears, nausea, rash, vomiting, vertigo Ethambutol Bacteriostatic Prevents formation of the cell wall 1 in 107 Decrease in visual acuity, colourblindness and other visual defects, joint pain, nausea, vomiting, fever, malaise, headache, dizziness Fluoroquinolones Bactericidal Act manly on DNA gyrase (DNA gyrase: introduces negative supercoils into DNA) Tendon damage, heart problems, swelling of face and throat, shortness of breath, rash, loss of consciouness Pyrazinamide Bacteriostatic, Bactericidal Accumuates causing cellular damage Joint pain, nauseau, vomiting, rash, malaise, fever, photosentivity Treatment
    • Drug Resistance and Tuberculosis - M. tuberculosis: naturally resistant to certain antibiotics due to presence of: - Drug-modifying enzymes - Drug-efflux systems - Hydrophobic cell wall - Mycobacteria undergo natural mutations which can lead to development of drug resistance. - TB is treated by administration of combination chemotherapy: decreases probability of development of drug resistance. - Development of increasingly resistant strains mainly due to: Patient non- compliance
    • MDR and XDR Tuberculosis MDR: Multidrug-resistant strains: - Strains of tuberculosis resistant at least to rifampicin and isoniazid. - Mortality rate: 40-60% - Estimated that 50 million people are infected with MDR-TB. - MDR-TB is approximately 125 times more expensive to treat than drug susceptible TB. XDR: Extensively-drug resistant strains: - Strains of tuberculosis resistant to rifampicin, isoniazid and at least three of the following classes of second-line drugs: aminoglycosides, polypetides, fluoroquinolones, thioamides, cycloserine and para-aminosalicylic acid.
    • MDR and XDR Tuberculosis - Emergence due to lack of patient compliance during TB treatment and inappropriate administration of TB drugs. - Results in more aggressive forms of TB. - Drug resistance does not increase infectiousness. - MDR and XDR-TB: uncommon in developing nations lacking TB drugs (high drug-susceptible TB rates) - MDR and XDR-TB rates are higher in developed nations with access to anti-TB drugs.
    • - HIV pandemic has reversed much of the progress made in the past few decades in combating TB. - People with latent TB have a 10-20% of developing active TB in their lifetime. People with HIV and latent TB are 100 times more likely to develop active TB. - HIV/AIDS leads to a compromised immune system: - HIV infects CD4+ T cells, macrophages, dendritic cells. - Result: decreased CD4+ T cells due to apoptosis of infected cells, CD8+ T cell mediated killing of infected cells - The numbers of CD4+ T cells progressively decline (loss of cell-mediated immunity) and the body is much more susceptible to infection Tuberculosis and HIV/AIDS T cell
    • - A person with HIV/AIDS will have a harder time fighting off the M. tuberculosis infection due to a compromised immune system. - HIV infection can cause latent M. tuberculosis infection to become reactivated. - TB is the leading cause of death for people with HIV/AIDS: mean survival rate is 430 days. - MDR and XDR-TB and HIV/AIDS: - Additional symptoms: excessive weight loss, respiratory problems (including the formation of lesions in the lungs). - Mean survival rate: 45 days. Tuberculosis and HIV/AIDS
    • Directly Observed Treatment  Why? Many patients don’t take medicines regularly, even if excellent health education provided  Who? All patients... impossible to predict which patient will take medicine (1/3 not adherent)  What? Observer watches and helps patient swallow tablets  Where? Anywhere! (home, clinic, work, school, etc)  Who does it? HCW, community liaisons, teachers, Direct observation ensures treatment for entire course with the right drugs, in the right doses, at the right intervals
    • DOT is necessary even when drug supply ensured 88% 61% 0% 20% 40% 60% 80% 100% Chaulk CP. JAMA 1998;279:943-8 Treatment Success DOT No DOT